Erectile dysfunction (ED) is an evolving health problem with growing incidence in the ageing male population with potentially predictive value for cardiovascular and other chronic diseases. ED shares the common cardiovascular risk factors. The aetiology of ED is numerous including neurogenic, psychogenic, arteriogenic, and venogenic reasons. The origin of arteriogenic ED is frequently atherosclerosis. Patients not adequately responding to conservative measures including oral medication are often referred to further vascular diagnostics and therapy. At present, the refi nements in endovascular therapy allow for minimal-invasive revascularization of erection-related arteries. The role of endovascular therapy in the complex framework of the multifactorial causes of ED requires further scientifi c scrutiny.
Introduction
Erectile dysfunction (ED) has become an increasing health problem with growing prevalence in the ageing male population. Its prevalence is age-dependent and ranges from 2 % in younger (< 40 years) to 86 % in older men (> 80 years) [1] . Worldwide, more than 150 million men are expected to suff er from ED [2, 3] . In addition to the patients' psychological strains, ED is frequently representative for underlying atherosclerosis. Therefore, it is not surprising that ED shares the common cardiovascular risk factors. Furthermore, ED is often associated with other chronic diseases i. e. coronary artery disease [4] [5] [6] [7] or obstructive sleep apnoea syndrome [8, 9] . Montorsi et al. reported a 70 % prevalence of ED in a consecutive series of 300 patients presenting with acute chest pain and angiographically documented coronary artery disease [4] . In addition, ED patients have an increased risk (relative risk: 1.48 [95 %-CI: 1.24-1.74]) to suff er from cardiovascular disease when compared to non-ED patients. [7] . Thereby, younger ED patients (< 40 years) are even more prone to experience a cardiovascular event with an incidence of > 7 times when compared to a healthy control group [10] . Similarly, an ED prevalence of > 60 % was reported in patients presenting with obstructive sleep apnoea syndrome [8, 9] .
In line with these observations, there is an increasing interest in ED for healthcare providers, not only for its nective tissue and build-up blood-fi lled spaces. These expandable spongy formations are covered with the dense tissue tunica albuginea. Arterial supply to the penis is provided by the paired penile arteries arising from the internal pudendal artery, a branch of the internal iliac artery. The penile artery has four terminal branches: the cavernous, dorsal, bulbar, and urethral arteries. Venous outfl ow results from post cavernous venules, which form emissary veins and drain into the cavernous, the deep dorsal, and the superfi cial dorsal veins. The innervation of the erectile tissue is provided by parasympathetic, sympathetic, and somatic nerves.
The stimulus for erection either comes from the central nervous system (supraspinal centres) or from the peripheral nervous system by mechanical stimulation of the dorsal nerve of the penis. Penile erection results from a complex cascade of nervous, vascular, hormonal, and psychological actions. During the fl accid state, blood fl ow to the penis is limited via anti-erectile neural inputs, particularly mediated by sympathetic eff erents. By mechanical or psychological sexual stimulation parasympathetic tracts get activated and erectile response is initiated via neurotransmitter release onto postsynaptic smooth muscle cells. This includes the release of several neurotransmitters from the cavernosal nerve terminals and endothelial cells: nitric oxide (NO), vasoactive intestinal polypeptide, acetylcholine, and several prostaglandins.
Of these, NO is considered to be the most important neurotransmitter for penile erection. After diff usion into smooth muscle cells, NO activates the soluble guanylyl cyclase enzyme. This induces the production of the second messenger cyclic guanosine monophosphate (cGMP), which leads to a decrease in intracellular Ca2 and to relaxation of the smooth musculature of the arteries. Consequently, arterial perfusion to the corpora cavernosa is increased while compression of the subtunical venous plexus reduces venous outfl ow (veno-occlusive mechanism). As a result of these mechanisms, the intracavernous pressure increases up to three to four times leading to penile erection. After ejaculation, neural adrenergic fi bres release noradrenaline. This promotes the phosphodiesterase type-5 (PDE-5) enzyme to hydrolyze cGMP to the inactive guanosine monophosphate. As a result, intracellular Ca2+ rises, smooth muscles contract, and pressure decreases by restored venous outfl ow.
Based on these physiological mechanisms, reasons for ED can be classifi ed as neurogenic, arteriogenic, and venogenic. Thereby, neurogenic causes (i. e. central nervous system, psychological problems) include any problem with initiating the subsequent vascular reactions. Arteriogenic problems involve any reason for not adequately fi lling the penis with blood, and any failure of the veno-occlusive system is referred to as a venogenic problem. In these patients, dysfunction of the corporal smooth muscle cells leads to incomplete resistance of the blood outfl ow from the corpora [14] . This results in venous leakage, which is frequently associated with an incomplete erection.
The association of ED and cardiovascular events is based on the common pathophysiological mechanisms of endothelial dysfunction [15] , infl ammation [16] , and low testosterone levels [15, 17] .
Non-invasive diagnostic work-up

Patient history
The most important tool of non-invasive ED diagnostic is to obtain a proper patient history. General anamnesis focuses on cardiovascular risk factors, family history of ED, and a description of the functional problems associated with ED. Thereby, regular nocturnal and early morning erections are of predictive value to rule out vasculogenic ED [18] . Nocturnal penile tumescence monitorings are performed by nocturnal electrobioimpedance volumetric assessment [19] . Of note, nocturnal and early morning erections come along with rapid eye movement sleep, which decreases in ageing men [20, 21] . Furthermore, the thorough patient history includes the IIEF questionnaire (ESM 1, ESM 2). In addition, a history of drug-intake is required (i. e. antihypertensive medication, antidepressants, antiandrogenic agents) as well as the already applied therapeutic strategies (i. e. phosphodiesterase inhibitors, vacuum pump, intracavernous injection).
Clinical examination
This involves examination of the genitourinary system including palpation of the prostate and searching for signs of hypogonadism (body hair, characteristics of other men in family, temporal hair recession, full male musculature, deep voice, small testes (< 20 ml), small phallus (< 8 cm), gynecomastia, and length of the long bones). Furthermore every patient must be given a neurological status and an examination of the peripheral pulses, oscillometry, and ankle-brachial index (ABI). The value of the ABI assessment in patients with suspected ED is confl icting. ED was shown to be an independent predictor of peripheral artery disease (PAD) defi ned as an ABI < 0.9 [22] . On the other hand, an ABI of < 0.9 is of limited predictive value to diagnose ED in the general population [23] . Only in diabetic and cardiovascular highrisk patients (Framingham Risk Score), an ABI of < 0.9 may be associated with and be predictive for ED [23] . In line, cardiovascular risk stratifi cation in patients with suspected ED using the Framingham Risk Score is promoted by some in order to determine the diagnostic work-up [24] .
Laboratory testing
Men with a diminished libido may suff er from low serum testosterone and may benefi t from hormone replacement. Diagnose and therapy should be performed in close collaboration with endocrinologist and prostatic cancer should be excluded. Laboratory testing incorporates checking for hypothalamic-pituitary and/or gonadal disorder. The general laboratory testing includes: LH, FSH, testosterone levels, and GnRH. In addition, a glucose and lipid profi le testing is recommended. Of note, testing of testosterone levels is particularly recommended in patients with failed PDE-5 inhibitor treatment [24] . Testosterone levels < 200 ng/dl are considered low and supplementation may be considered [25] .
Medical treatment
As in other cardiovascular pathologies, lifestyle modifi cations are important. Many men with erectile dysfunction may benefi t from smoking cessation, weight loss, physical activity, reduction of alcohol intake/stop drug consumption or solve relationship problems [26] .
Nevertheless, therapy should be customized. If there is no success in spite of lifestyle modifi cations, oral medications are often the next approach for erectile dysfunction therapy. There are oral substances available to treat psychogenic ED i. e. yohimbin, an alkaloid with α-2 antagonistic eff ects in the central nervous system. However, these medications are not recommended by the German (DGU: Deutsche Urologie Gesellschaft) and the American Urological Association (AUA). Testosterone supplementation is controversial but may be considered in patients with low testosterone levels presenting concomitantly with abnormal nocturnal erections [25, 27] .
For vasculogenic ED, PDE-5 inhibitors are the most commonly used medications and recommended as fi rstline treatment unless there are contraindications including myocardial or cerebral infarction within six weeks, angina pectoris, intake of nitrate drugs, cardiac arrhythmia, retinitis pigmentosa, or renal and hepatic insuffi ciency [28] . They are chosen depending on the onset of action, duration of action, and possible side eff ects.
To avoid long-acting side eff ects, patients without experience should receive substances with short duration of action. However, about 50 % of patients would not be responsive. But before being classifi ed as non-responders, eight attempts should be carried out. There are diff erent PDE-5 inhibitors on the market varying slightly in half-life but sildenafi l (Viagra®) is the most frequently used and prescribed agent.
If oral therapy is not successful or appropriate, there are non-oral treatment options such as intracavernous self-injections, penis pumps or surgical methods.
However, it is important to keep in mind that ED may present as a side eff ect of concomitant medications such as beta blockers for antihypertensive therapy. Several studies reported impaired sexual function in patients taking beta blocker medication [29, 30] . In patients with concomitant and indicated beta blocker therapy, switching to a novel third-generation β-1 blocker, e. g. nebivolol, with a greater degree of selectivity for β-1 adrenergic receptors is reasonable. Compared to other agents, nebivolol has a very low risk of sexual side eff ects [31] . Some reports even attribute nebivolol with positive eff ects on erectile function based on favorable NO modulation [32] .
In addition, the eff ects of statin therapy in ED patients remain confl icting [33] . In animal models, statin therapy was shown to have benefi cial eff ects on the endothelium and to increase NO concentrations [34] . In line, it is hypothesized that statin therapy may improve the NO mechanism and thus, increase the effi cacy of concomitant PDE-5 therapy [35] [36] [37] . However, statin therapy was also shown to impair testosterone synthesis with adverse eff ects on penile erection [38] . Overall, statin therapy alone [39] , as well as in combination with PDE-5 inhibitor therapy, was shown to improve the sexual health related quality of life in ED patients but may not be considered an erectogenic drug [40] . Nevertheless, it is suspected that statin therapy may improve the effi cacy of PDE-5 inhibitor therapy in patients with endothelial dysfunction [40] .
In case of non-responsiveness to all these treatment strategies, no evident reason for any adverse eff ects of co-medication and reasonable suspicion of vasculogenic ED, further diagnostics and invasive therapy may be considered. Figure 1 provides an algorithm for diagnostics in ED patients.
Arterial imaging and endovascular therapy of arteriogenic ED
Arteriogenic ED may aff ect diff erent arteries and was shown to present with a great variety of lesion patterns. In patients with suspected arteriogenic ED, duplex ultrasound is recommended for primary arterial examination. However, duplex sonography may be challenging and also limited to the common and proximal internal iliac arteries as well as the penile arteries. The pudendal arteries are not visualizable at all but can only be assessed by indirect examination of the distal penile artery. Proper duplex ultrasound examination of the penis artery (profound penis artery) is only possible after intracavernous injection of alporostadil (PGE-1). In general, the application of 5 ug PGE-1 is sufficient for proper stimulation. However, in ED patients with an underlying vasculogenic disorder, doses of 10-20 ug may be necessary to attain a proper erection. In the erected penis, a peak-systolic velocity > 0.3 m/s and a resistance index > 0.8 in the penile artery are considered normal [41] . An increased end-diastolic velocity (> 0.05 m/s) implying low arterial resistance is considered to indicate a problem with the penile veno-occlusive mechanism [42] .
In patients with suspected arteriogenic ED, a computed tomography angiogram (CTA) or magnetic resonance angiography (MRA) is recommended for further distinction of macro versus microangiopathic disease. Based on the imaging, diagnostic angiography, and percutaneous revas-cularization is suggested as a next step, particularly in patients with macroangiopathic disease (Figure 1 ). Of note, endovascular revascularization is no option in microangiopathic disease. In general, a CTA is preferred for the following reasons: better availability and time-saving investigation as well as it being the favourable imaging modality for the assessment of calcifi cation (i. e. diff erentiation of calcifi ed versus soft plaques).
Von Allmen et al. published data on lesion morphology of 26 patients not responsive to PDE-5 inhibitors and thus, suspected to suff er from arteriogenic ED [43] . Arterial lesions were assessed by angiography and classifi ed as macro and microangiopatic. Macroangiopathy was defi ned as > 70 % stenosis of the main arteries including the internal pudendal artery. Microangiopathy represented small (< 1 mm) arteries distal to the internal pudendal circulation i. e. penile arteries that were rarefi ed or occluded with a lack of adequate reconstitution. Seventeen macroan-giopathic lesions were observed involving the common (n = 2), internal iliac (n = 10), and internal pudendal artery (n = 5) in 11 patients. Microangiopathy was observed in seven patients and the remaining eight patients revealed no arteriopathy. Interestingly, patients presenting with macroangiopathic disease were shown to have a higher prevalence of PAD (63.6 % vs. 6.7 %, p = 0.003).
Usually, a retrograde puncture of the contralateral common femoral artery is performed. After catheterization of the common iliac artery (Figure 2) , angiographic imaging of the common, external, and internal arteries is performed. Thereafter, if necessary, the catheter is advanced into the hypogastric artery and pudendal artery for selective angiography. The latter is frequently and successfully engaged with a 0.014 guidewire.
To date, no specifi c guidance based on clinical studies exist, as to whether stenting is superior to balloon angioplasty in these oftentimes small-calibre arteries. Balloon angioplasty of the pudendal artery was shown to restore blood fl ow and substantially improve the symptoms of ED during short-term follow-up [44] . However, it is noteworthy that arteriogenic ED is accompanied by a veno-occlusive disorder in up to 80 % of patients [43] . The value of intra-arterial pressure gradient measurements is unclear.
The recently published PERFECT-2 Study [45] evaluated balloon angioplasty for isolated penile artery stenoses (n = 34 lesions) in 22 ED patients. The primary endpoint was in-segment restenosis (≥ 50 %) by CTA at the eightmonth follow-up. One year sustained clinical success (IIEF-5 score ≥ 22 or maintaining a ≥ 4 improvement to baseline) was considered as secondary endpoint. Mean lesion length was 11.1 ± 9.0 mm and the mean IIEF-5 score at baseline was 10. Furthermore, the ZEN trial by Rogers et al. evaluated drug-eluting stenting (with Zotaralimus) for the treatment of ED in patients with suboptimal response to PDE-5 inhibitors [42] . Within this prospective trial, a total of 30 patients (45 internal pudendal artery lesions) were treated with drug-eluting stent in a multicentre but single-armed setting. Mean lesion length was 18 mm and procedural success rate was 100 %. During follow-up, no stent fracture was observed. The primary feasibility endpoint, defi ned as an improvement of IIEF score ≥ 4, was achieved in 59.3 % of patients at the six-month follow-up. Binary restenosis (≥ 50 % lumen compromise by angiography) was reported in 34.4 % at the same interval. Based on these fi ndings, drug-eluting stenting of the pudendal arteries is considered safe and benefi cial to the majority of patients. Nevertheless, the rate of non-responders was rather high (40.1 %), which may be attributed to microangiopathy frequently observed in ED patients [43] and to other co-morbidities.
The most common pathophysiological mechanisms of arterial ED is atherosclerosis. Not surprisingly, ED shares the common cardiovascular risk factors [6] as outlined in Table I . Of interest, ED frequently precedes coronary and peripheral artery disease by two to fi ve years (mean three years) [5, 6] . Nevertheless, there is a remaining gap in evidence on routine screening for ED in men. In addition to atherosclerosis, arterial ED may occur iatrogenically in consequence of diff erent reasons for iliac artery occlusion. In some patients, the internal iliac artery may be shuttered i. e. due to the iliac branch in patients undergoing endovascular aortic aneurysm repair. Other men may lose one or even both internal iliac arteries because of arterial embolization for the treatment of aneurysm. Furthermore, there have been controversial postoperative incidences of ED reported after open and endovascular aortic repair [46, 47] .
Venous imaging and endovascular therapy of venogenic ED
In patients with suspected veno-occlusive dysfunction (i. e. high end-diastolic velocities), dynamic cavernosometry and cavernosography (DICC) is considered the goldstandard for diagnostics [14] . Dynamic cavernosometry requires the injection of an erection promoting drug to obtain a rigid erection. Thereafter, a fl uid is pumped into the penis with known rate and pressure. This allows to obtain information about the pressure within the corpora cavernosum during penis erection. For cavernosography, contrast medium is injected to visualize any venous leakage by X-ray screening during penis erection.
In case of venous-occlusive dysfunction, the primary treatment strategy is to cut off venous leakage. Surgical therapy involves ligation of the deep dorsal vein and its collaterals. However, this treatment strategy is invasive, is performed under general anaesthesia and usually requires the patient to stay in the hospital for three days. The long-term success of ligation of the deep dorsal vein and its collaterals is reported to be 25 % [48, 49] . In addition to surgical ligation therapy, endovascular embolization therapy is considered a less invasive option. Aschenbach et al. reported their experience of endovascular embolization in 29 men with ED due to veno-occlusive dysfunction confi rmed by DICC [50] . The embolization procedure was performed via transfemoral access using N-butyl-2-cynoacrylate (Histoacryl). No complications were observed and technical success was obtained in 27/29 (93.1 %) of patients. The two failures were attributed to anatomical reasons. Clinical success was achieved in 24/27 (88.8 %) of patients.
The exact prevalence of veno-occlusive disorders in ED patients remains unclear. In general, primary diagnostics are focusing on arterial pathologies. However, arteriogenic ED may be accompanied by a venogenic disorder in up to 80 %. This in addition to microangiopathic disease, other co-medication, and co-morbidities may be the main reason for the rather high rate of non-responding ED patients. In line, a proper patient history and thorough diagnostic approach is mandatory in ED patients.
Conclusions
The prevalence and awareness of ED is increasing for various reasons. In addition to the psychological strains for men and their partners, ED is closely related to cardiovascular diseases. ED shares the common cardiovascular risk factors but moreover, was shown to precede cardiovascular events by about three years. In addition to the arterial Table I . Overview on the common cardiovascular risk factors associated with erectile dysfunction (ED) [6] . pathophysiologies, ED patients frequently suff er from veno-occlusive disorders.
Age
In consequence, patient history shall incorporate ED for its predictive value as well as to provide men suff ering from ED with a proper diagnosis and therapy.
At present, the refi nements in endovascular therapy allow for minimal-invasive revascularization of erectionrelated arteries. Its role in the complex framework of the multifactorial causes of ED requires further scientifi c scrutiny.
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